Search

everythinglearnresearchcommunity

for

Search:↓

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

MK-5108 is safe and shows potential against tumors, especially alone.

Upadacitinib effectively treats severe alopecia areata and is safe.

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

Individual choice in treating alopecia areata greatly impacts quality of life.

The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

The Brigham Eyelash Tool for Alopecia (BELA) is a reliable way to measure eyelash loss in alopecia areata patients.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

CTP-543 is generally safe for treating alopecia areata.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Start with 2.5 mg/mL triamcinolone acetonide for scalp alopecia areata and increase if needed.

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

Baricitinib was effective in treating alopecia areata in two major trials.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Alefacept does not effectively treat severe alopecia areata.